title: Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats.
abstract: In this study, we investigated whether components of pomegranate could inhibit CYP3A-mediated drug metabolism. The ability of pomegranate to inhibit the carbamazepine 10,11-epoxidase activity of CYP3A was examined using human liver microsomes, and pomegranate juice was shown to be a potent inhibitor of human CYP3A. Addition of 25 microl (5.0% v/v) of pomegranate juice resulted in almost complete inhibition of the carbamazepine 10,11-epoxidase activity of human CYP3A (1.8%). The inhibition potency of pomegranate juice was similar to that of grapefruit juice. In addition, we investigated the in vivo interaction between pomegranate juice and carbamazepine pharmacokinetics using rats. In comparison with water, the area under the concentration-time curve (AUC) of carbamazepine was approximately 1.5-fold higher when pomegranate juice (2 ml) was orally injected 1 h before the oral administration of the carbamazepine (50 mg/kg). On the other hand, the elimination half-life of carbamazepine and the AUC ratio of carbamazepine 10,11-epoxide to carbamazepine were not altered by the injection of pomegranate juice. These data suggest that pomegranate juice component(s) impairs the function of enteric but not hepatic CYP3A. Thus, we discovered that a component(s) of pomegranate inhibits the human CYP3A-mediated metabolism of carbamazepine. Furthermore, pomegranate juice alters the carbamazepine pharmacokinetics in rats.
authors.affiliation: Department of Pharmacy, Miyazaki Medical College Hospital, Kiyotake-cho, Miyazaki-gun, Japan. yshidaka@med.miyazaki-u.ac.jp
authors.forename: Muneaki
authors.initials: M
authors.lastname: Hidaka
authors.forename: Manabu
authors.initials: M
authors.lastname: Okumura
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Fujita
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Ogikubo
authors.forename: Keishi
authors.initials: K
authors.lastname: Yamasaki
authors.forename: Tomomi
authors.initials: T
authors.lastname: Iwakiri
authors.forename: Nao
authors.initials: N
authors.lastname: Setoguchi
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Arimori
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism*; D001628:Beverages; D002220:Carbamazepine / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D051544:Cytochrome P-450 CYP3A; D018565:Food-Drug Interactions; D006801:Humans; D066298:In Vitro Techniques; D029561:Lythraceae; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D010089:Oxidoreductases, N-Demethylating / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013056:Spectrophotometry, Ultraviolet
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine; D001189:Aryl Hydrocarbon Hydroxylases; D051544:Cytochrome P-450 CYP3A; D010089:Oxidoreductases, N-Demethylating